Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions. Kontoghiorghes, G. J., Efstathiou, A., Kleanthous, M., Michaelides, Y., & Kolnagou, A. Hemoglobin, 33(5):386–397, 2009. Place: England
doi  bibtex   
@article{kontoghiorghes_riskbenefit_2009,
	title = {Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron  loading conditions.},
	volume = {33},
	issn = {1532-432X 0363-0269},
	doi = {10.3109/03630260903217141},
	language = {eng},
	number = {5},
	journal = {Hemoglobin},
	author = {Kontoghiorghes, George J. and Efstathiou, Aglaia and Kleanthous, Marios and Michaelides, Yiannis and Kolnagou, Anita},
	year = {2009},
	pmid = {19814684},
	note = {Place: England},
	keywords = {Animals, Antioxidants/*therapeutic use, Benzoates/therapeutic use, Chelation Therapy, Copper/metabolism, Deferasirox, Deferiprone, Deferoxamine/therapeutic use, Free Radicals/metabolism, Humans, Iron Chelating Agents/*therapeutic use, Iron Overload/complications/*drug therapy, Iron/metabolism, Oxidative Stress/*drug effects, Pyridones/*therapeutic use, Risk Assessment, Siderophores/therapeutic use, Thalassemia/*drug therapy, Triazoles/therapeutic use},
	pages = {386--397},
}

Downloads: 0